Abstract
IntroductionDiabetic sensorimotor polyneuropathy (DSPN) affects approximately 30% of people with diabetes, while around half of cases are symptomatic. Currently, there are only few pathogenetically oriented pharmacotherapies for DSPN, one of...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have